2 weeks Ago By Defense World Staff
Brandes Investment Partners LP increased its holdings in Grifols, S.A. ( NASDAQ:GRFS – Free Report ) by 8.
7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 18,596,790 shares of the biotechnology company’s stock after purchasing an additional 1,481,924 shares during the quarter. Grifols accounts for 1.
4% of Brandes Investment Partners LP’s investment portfolio, making the stock its 26th biggest position. Brandes Investment Partners LP owned 2.70% of Grifols worth $117,242,000 as of its most recent SEC filing.
Several other hedge funds have also added to or reduced their stakes in GRFS. Cohen Investment Advisors LLC bought a new position in shares of Grifols during the first quarter valued at about $80,000. AQR Capital Management LLC purchased a new position in shares of Grifols during the second quarter valued at approximately $89,000.
Cetera Advisors LLC purchased a new stake in Grifols in the first quarter worth $147,000. China Universal Asset Management Co. Ltd.
increased its position in Grifols by 66.3% during the 1st quarter. China Universal Asset Management Co.
Ltd. now owns 23,461 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 9,350 shares during the period. Finally, Morningstar Investment Services LLC purchased a new stake in shares of Grifols in the 4th quarter worth about $186,000.
Grifols Stock Performance Shares of NASDAQ GRFS opened at $8.95 on Monday. Grifols, S.
A. has a 1 year low of $5.30 and a 1 year high of $12.
15. The company’s 50-day moving average is $8.23 and its 200 day moving average is $7.
44. The company has a current ratio of 1.68, a quick ratio of 0.
80 and a debt-to-equity ratio of 1.06. About Grifols ( Free Report ) Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. Read More Five stocks we like better than Grifols The Significance of Brokerage Rankings in Stock Selection 3 Bargain Stocks Under $20 With Major Growth Potential What to Know About Investing in Penny Stocks Top 5 ETFs to Own Now and Into 2025 Stock Market Upgrades: What Are They? Watch These 3 Former Short-Squeeze Stocks for a Big Rally Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Grifols, S.
A. ( NASDAQ:GRFS – Free Report ). Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.
com's FREE daily email newsletter ..
